[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pandemic Science, Vaccines soon", "description": "University of Oxford and AstraZeneca\n\nDevelopment of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups (AZ, 31st August)\n\nhttps://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html\n\nhttps://www.inverse.com/mind-body/3-coronavirus-vaccines-explained\n\nAZD1222\n\nBased on a chimpanzee adenovirus\n\nUS, $1.2 billion\n\nEU, ordered 400 m doses\n\n1st deliveries October\n\nCan make 2 billion doses\n\nMillions already produced in India\n\nSo far\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext\n\nN = 543\n\n14 days after receiving the vaccine\n\n91% to 100% produced neutralizing antibodies\n\nAnti-spike IgG\n\nThese antibodies prevent viruses from infecting healthy cells\n\nTherefore, likely to protect against COVID-19\n\nLocal and systemic reactions\n\nNo serious adverse events\n\nPhase 3, 28 June, Brazil\n\nNow\n\nFinal testing stage in US\n\nEnrolment for phase 3 clinical trials opened\n\n30,000 adults, aged 18 years or over\n\nDiverse racial, ethnic, and geographic groups\n\nHealthy or have stable underlying medical conditions\n\nRandomly assigned\n\nSaline control, or two doses of AZD1222,\n\nFour weeks apart\n\nTwice as many people will receive the vaccine than not\n\nTesting for efficacy and safety\n\nThe immune responses of 3,000 evaluated in detail\n\nOther late-stage AZD1222 trials have already begun in South Africa, Brazil, India, United Kingdom\n\nRussia and Japan soon,\n\n50,000 participants worldwide\n\nTHE MODERNA VACCINE CANDIDATE, MRNA-1273 \n\nhttps://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins\n\nSo far\n\nOne dose caused some to produce binding antibodies\n\nTwo doses caused all to produce neutralizing antibodies\n\nAugust 11, US, an additional $1.5 billion\n\n\nMessenger RNA (mRNA)\n\nadenine, cytosine, uracil, guanine\n\nTranslation in the cytoplasm\n\nRibosomes\n\nCopy of part of the virus's genetic sequence\n\nProtected by a lipid nanoparticle\n\nDirects cells to make a protein that works as a drug or vaccine\n\nNow\n\nPhase 3 clinical trials began July 27\n\n30,000 healthy adults \n\n2 doses\n\nTest for safety\n\nIf the vaccine can prevent symptomatic COVID-19\n\n? how long will antibodies last\n\nTHE PFIZER/BIONTECH VACCINE CANDIDATE, BNT162B2 \n\nUS / German\n\nUS, $1.9 billion pre-order\n\nSo far\n\nmRNA vaccine\n\nGenerates antibodies virus-neutralizing antibodies\n\nGenerates T cells\n\nNow\n\nPhase 3 clinical trials started July 27\n\n30,000 health adults in the US\n\nExpected to expand to 120 sites globally. \n\nTwo-dose regime\n\nEncodes an optimized SARS-CoV-2 full-length spike glycoprotein\n\nWhich is the target of virus-neutralizing antibodies\n\nTo seek regulatory approval October\n\nUp to 100 million doses by the end of October 2020\n\nChina and Russia\n\nSkipped phase 3 trials\n\nNYT\nhttps://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html", "link": "https://www.youtube.com/watch?v=d-oQI2RoXPI", "date_published": "2020-09-02 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pandemic science, Wear a mask to protect yourself", "description": "All referenced hyperlinked below for personal perusal and verification. CDC\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html\n\nMasks reduce the spray of droplets when worn over the nose and mouth\n\nPrevent people who have COVID-19 from spreading virus to others\n\nRespiratory virus shedding in exhaled breath and efficacy of face masks (Nature Medicine)\n\nhttps://www.nature.com/articles/s41591-020-0843-2\n\nAerosol transmission is a potential mode of transmission for coronaviruses as well as influenza viruses and rhinoviruses\n\nUniversal use of face masks for success against COVID-19: evidence and implications for prevention policies (European Respiratory Journal)\n\nhttps://erj.ersjournals.com/content/55/6/2001260\n\nCloth masks are a simple, economic and sustainable alternative to surgical masks as a means of source control of SARS-CoV-2 in the general community\n\nMask wearers are dramatically less likely to get a severe case of Covid-19\n\nhttps://www.inverse.com/mind-body/masks-breathing-in-less-coronavirus-means-you-get-less-sick\n\nProfessor Monica Gandhi, San Francisco General Hospital. \n\nNo mask is perfect\n\nWearing one might not prevent you from getting infected\n\nBut it might be the difference between a case of Covid-19 that sends you to the hospital and a case so mild you don\u2019t even realize you\u2019re infected.\n\nMasks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer (Journal of General Internal Medicine)\n\nhttps://link.springer.com/article/10.1007/s11606-020-06067-8\n\nUniversal masking reduces the \u201cinoculum\u201d \n\nLeading to more mild and asymptomatic infection manifestations\n\nMasks, depending on type, filter out the majority of viral particles, but not all\n\nViral inoculum and severity of disease (LD50)\n\nRising rates of asymptomatic infection with population-level masking\n\nIncreased with mask wearing, decreased where few masks are worn\n\nSo, more asymptomatic infections\n\nGreater community-level immunity and slower spread\n\n\nCloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach (Annals of Internal Medicine)\n\nhttps://www.acpjournals.org/doi/10.7326/M20-2567\n\n\nThe point is not that some particles can penetrate but that some particles are stopped\n\nEvery virus-laden particle retained in a mask is not available to hang in the air as an aerosol or fall to a surface to be later picked up by touch.\n\nCloth can block droplets and aerosols, and layers add efficiency.\n\nImmunity and immunopathology to viruses: what decides the outcome? (Nature, Reviews Immunology)\n\nhttps://www.nature.com/articles/nri2802\n\nThe outcome of host\u2013viral interactions depend on\n\nDose and route of infection\n\nViral virulence properties\n\nSeveral host factors that mainly involve innate and adaptive immunity\n\nIf the exposure dose is very high, the immune response can become overwhelmed.\n\nIf the initial dose of the virus is small, the immune system is able to contain the virus with less drastic measures.\n\nIf this happens, fewer symptoms, if any\n\nA simple method of estimating fifty per cent end points, (American Journal of Hygiene, 1938)\n\nhttps://academic.oup.com/aje/article-abstract/27/3/493/99616?redirectedFrom=fulltext\n\n Viral dose being related to disease severity \n\nValidation of the Wild-type Influenza A Human Challenge Model H1N1pdMIST: An A(H1N1)pdm09 Dose-Finding Investigational New Drug Study (Clinical Infectious Diseases)\n\nhttps://academic.oup.com/cid/article/60/5/693/291415\n\nClinical symptoms of influenza occurred at all doses (Table 1), but were most prevalent at 106 and 107 TCID (tissue culture infectious dose)\n\nHigher viral doses, the more sick people became\n\nSimple Respiratory Protection\u2014Evaluation of the Filtration Performance of Cloth Masks and Common Fabric Materials Against 20\u20131000 nm Size Particles, (The Annals of Occupational Hygiene)\n\nhttps://academic.oup.com/annweh/article/54/7/789/202744\n\nMasks increase the rate of asymptomatic cases, (Annals of Internal Medicine)\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html\n\nhttps://theconversation.com/can-people-spread-the-coronavirus-if-they-dont-have-symptoms-5-questions-answered-about-asymptomatic-covid-19-140531\n\nhttps://www.acpjournals.org/doi/10.7326/M20-3012\n\nCOVID-19: in the footsteps of Ernest Shackleton, (MBJ, Thorax)\n\nhttps://thorax.bmj.com/content/75/8/693\n\nCases at seafood plant cause spike in Oregon COVID numbers (Pacific Seafoods)\n\nhttps://apnews.com/4b9d38f206db9ce5267a5898ac24f238\n\nReleases Covid-19 Test Results at Northwest Arkansas Facilities (Tyson)\n\nhttps://www.tysonfoods.com/news/news-releases/2020/6/tyson-foods-inc-releases-covid-19-test-results-northwest-arkansas", "link": "https://www.youtube.com/watch?v=DANEqOPcDwc", "date_published": "2020-09-01 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]